# Narratives: claude-opus-4-6

## Run 1 (79.0s)

# Toxicogenomic Dose-Response Interpretation Report

---

## 1. Biological Response Narrative

The 32 responsive genes (27 upregulated, 5 downregulated) across a BMD range of 0.2–20 reveal a coherent, dose-dependent progression from early adaptive cytoprotection to overt cellular damage, inflammation, and pro-apoptotic signaling.

### Ultra-Low Dose Range (BMD 0.2–0.55): Xenobiotic Sensing and Cytoprotective Activation

The earliest transcriptional responses involve activation of the **aryl hydrocarbon receptor (AHR) signaling axis** (median BMD 0.35), with upregulation of AHR and its canonical target genes **CYP1A1** and **CYP1B1**. This represents the molecular initiating event: ligand-dependent or stress-dependent activation of AHR, triggering Phase I xenobiotic metabolism. Concurrently, the **KEAP1-NFE2L2 (NRF2) pathway** is engaged at similarly low BMDs (median BMD 0.5–0.55), with upregulation of **NFE2L2** and its downstream targets **NQO1**, **HMOX1**, and **GCLC**. The chemical environment pathway (path:hsa05208/rno05208, median BMD 0.5) captures this integrated AHR-NRF2 response, involving 9 genes (AHR, CYP1A1, HIF1A, HMOX1, KEAP1, NFE2L2, NFKB1, NQO1, VEGFA). Metabolic pathways (path:rno01100, median BMD 0.5) and biosynthesis of cofactors (path:hsa01240, median BMD 0.55) are also activated, reflecting early metabolic reprogramming.

Notably, the NFE2L2-mediated nuclear events show mixed directionality at this stage, with KEAP1 expression changes suggesting a dynamic regulatory interplay between the negative regulator KEAP1 and the transcription factor NFE2L2—consistent with the canonical model of KEAP1-mediated NRF2 degradation being disrupted by electrophilic or oxidative stress.

### Low Dose Range (BMD 0.4–2.0): Ferroptosis Signaling and Early Stress Responses

Ferroptosis-related pathways (path:hsa04216/rno04216, median BMD 0.6) emerge with 3 genes upregulated, suggesting that oxidative lipid damage pathways are being engaged even at low doses. This is consistent with the upregulation of antioxidant genes (GPX1, SOD1, SOD2, CAT) observed in the GO enrichment for "response to oxidative stress" (GO:0006979) and "response to hydrogen peroxide" (GO:0042542). The activation of **HIF1A** at low BMDs further indicates that the cellular oxygen-sensing machinery is responding to redox perturbation, consistent with the GO term "response to hypoxia" (GO:0001666, 15 genes).

### Transitional Dose Range (BMD 2.0–4.0): Circadian Disruption, Autophagy, and Emerging Stress

A qualitative shift occurs in this range. **Circadian clock genes** are downregulated (median BMD 2.25), representing one of the few downregulated responses. Disruption of circadian regulation is increasingly recognized as a consequence of oxidative stress and NRF2 activation, and may reflect systemic metabolic dysregulation.

**Autophagy** (path:hsa04140/rno04140, median BMD 3.5) and **mitophagy** (path:hsa04137/rno04137, median BMD 3.5) pathways are activated, with upregulation of **SQSTM1** (p62), a key autophagy receptor and NRF2 pathway modulator. This represents an intermediate adaptive response—cells are attempting to clear damaged organelles and protein aggregates. The **Wnt signaling pathway** (path:hsa04310, median BMD 3.75) shows mixed directionality, suggesting complex regulation of cell fate decisions.

The fluid shear stress and atherosclerosis pathway (path:hsa05418/rno05418, median BMD 4.0) engages 11 genes including BCL2, HMOX1, IL1B, KEAP1, NFE2L2, NFKB1, NQO1, SQSTM1, TNF, TP53, and VEGFA—indicating that vascular and endothelial stress responses are becoming prominent.

### Moderate Dose Range (BMD 4.0–6.0): Cancer-Related Pathways, p53 Activation, and Inflammatory Signaling

This range marks the transition from predominantly adaptive to overtly adverse responses. The **pathways in cancer** (path:hsa05200/rno05200, median BMD 5.0) engage 15 genes, representing the most enriched pathway in the dataset (p = 5.92 × 10⁻³⁸). Key cancer-associated genes including **TP53**, **CDKN1A** (p21), **BAX**, **BCL2**, **CASP3**, and **STAT3** are upregulated, indicating activation of tumor suppressor and cell cycle arrest programs.

The **p53 signaling pathway** (path:hsa04115/rno04115, median BMD 5.5) is activated with 5 genes, and TP53-regulated transcription of cell cycle genes (median BMD 5.25) and cell death genes (median BMD 5.75) are engaged sequentially. This temporal ordering—cell cycle arrest preceding apoptotic commitment—is biologically coherent and suggests that cells initially attempt growth arrest before committing to programmed cell death.

The **PI3K-Akt signaling pathway** (path:hsa04151, median BMD 5.25) and **HIF-1 signaling** (path:hsa04066, median BMD 5.0) are activated, reflecting survival signaling that competes with pro-apoptotic programs. **Cell cycle** pathway activation (path:hsa04110, median BMD 5.0) with CDKN1A upregulation indicates G1/S checkpoint engagement.

Multiple organ-specific disease pathways emerge: **hepatocellular carcinoma** (path:hsa05225, median BMD 2.65), **renal cell carcinoma** (path:hsa05211, median BMD 4.25), **gastric cancer** (path:hsa05226, median BMD 5.5), **bladder cancer** (path:hsa05219, median BMD 4.5), and **prostate cancer** (path:hsa05215, median BMD 5.25).

### Moderate-High Dose Range (BMD 6.0–10.0): Inflammation, Apoptosis, and Tissue Damage

**Apoptosis** pathways (path:hsa04210, median BMD 7.0) are fully engaged with 6 genes, and the BH3-only protein activation pathway (median BMD 5.75) indicates mitochondrial apoptotic commitment. The BAX/BCL2 ratio shift, combined with CASP3 upregulation, signals execution of the intrinsic apoptotic program.

**Pro-inflammatory cytokine signaling** intensifies: **TNF**, **IL1B**, and **IL6** are upregulated at higher BMDs, driving NF-κB signaling (path:hsa04064, median BMD 9.5), TNF signaling (path:hsa04668, median BMD 10.0), and IL-17 signaling (path:hsa04657, median BMD 10.0). The **NLRP3 inflammasome** is activated, as evidenced by NLRP3 upregulation and the inflammasome pathway engagement (median BMD 12.0).

The **AGE-RAGE signaling pathway in diabetic complications** (path:hsa04933, median BMD 8.75) involves 10 genes and reflects advanced glycation and inflammatory tissue damage. **Necroptosis** (path:hsa04217, median BMD 8.5) with 7 genes indicates that programmed necrotic cell death is occurring alongside apoptosis.

**JAK-STAT signaling** (path:hsa04630, median BMD 7.0) and **MAPK signaling** (path:hsa04010, median BMD 9.0) are activated, reflecting broad stress-responsive kinase cascades. The **senescence-associated secretory phenotype (SASP)** pathway (median BMD 10.25) indicates cellular senescence with pro-inflammatory cytokine secretion.

### High Dose Range (BMD 10.0–20.0): Immune Activation, Fibrosis, and Systemic Toxicity

At the highest doses, **innate and adaptive immune pathways** dominate: Toll-like receptor signaling (path:hsa04620, median BMD 10.5), NOD-like receptor signaling (path:hsa04621, median BMD 10.5), RIG-I-like receptor signaling (path:hsa04622, median BMD 9.5), and cytokine-cytokine receptor interaction (path:hsa04060, median BMD 11.0). These reflect a systemic inflammatory state with immune cell recruitment and activation.

**TGFB1** upregulation drives fibrotic signaling through TGF-beta (path:hsa04350, median BMD 12.5) and contributes to tissue remodeling. The inflammatory bowel disease pathway (path:hsa05321, median BMD 10.5) and rheumatoid arthritis pathway (path:hsa05323, median BMD 11.0) reflect chronic inflammatory tissue damage patterns.

**Neurodegenerative disease pathways** are activated at moderate-to-high doses: Alzheimer's disease (path:hsa05010, median BMD 10.0), Parkinson's disease (path:hsa05012, median BMD 5.0), amyotrophic lateral sclerosis (path:hsa05014, median BMD 5.75), and Huntington's disease (path:hsa05016, median BMD 6.0), reflecting mitochondrial dysfunction and neuronal stress.

---

## 2. Organ-Level Prediction

### Primary Target Organs

**Liver (Highest Confidence)**
The liver emerges as the primary target organ based on multiple converging lines of evidence. The organ signature analysis identifies 31+ responsive genes with liver annotation, the highest gene count of any organ. The AHR-CYP1A1/CYP1B1 axis is a canonical hepatic xenobiotic metabolism pathway, and AHR has been validated as a quantitative transcriptional biomarker for drug-induced liver injury (DILI) prediction (Quantitative Transcriptional Biomarkers of Xenobiotic Receptor Activation, 2020). The NRF2-KEAP1-NQO1-HMOX1-GCLC pathway is a well-characterized hepatoprotective response that, when overwhelmed, transitions to hepatotoxicity. NFE2L2 activation has been specifically linked to a "novel mechanism of hepatotoxicity involving endoplasmic reticulum stress and Nrf2 activation" (Toxicogenomic module associations with pathogenesis, 2017). PPARA activation is a liver-specific response associated with lipid metabolism perturbation (Fenofibrate differentially activates PPARα-mediated lipid metabolism, 2025). The hepatocellular carcinoma pathway (path:hsa05225) is activated at a relatively low median BMD of 2.65, and cadmium-induced toxicity in hepatic macrophages (Kupffer cells) specifically involves NF-κB and NRF2 activation (Research Advances on Cadmium-Induced Toxicity in Hepatic Macrophages, 2026). The enrichment of HMOX1 in hepatic Kupffer cells (671.56× enrichment) further supports hepatic immune-mediated injury.

**Kidney (High Confidence)**
The kidney is the second most likely target organ, with 26+ responsive genes annotated to renal tissue. HMOX1 enrichment in renal tubular epithelium (671.56×) indicates tubular injury responses. The gene expression pattern—including BAX, BCL2, CASP3, CDKN1A, CYP1A1, CYP1B1, GCLC, GPX1, HMOX1, NFE2L2, NFKB1, NQO1, SOD1, SOD2, TGFB1, TNF, TP53, and VEGFA—recapitulates known nephrotoxicity signatures. Nanocurcumin modulation of VEGF and AhR pathways in doxorubicin-induced nephrotoxicity (Aryl Hydrocarbon Receptor and Vascular Endothelial Growth Factor, 2026) directly supports the relevance of these pathways to renal injury. The AGE-RAGE pathway in diabetic complications (median BMD 8.75) is particularly relevant to renal pathology.

**Brain/Central Nervous System (High Confidence)**
Neuronal tissues show extensive gene enrichment: neurons (184.68×, 11+ genes), brain tissue (447.71×), and neurodegenerative tissues (503.67×). The gene signature includes BAX, BCL2, CASP3, IL1B, IL6, NFE2L2, SIRT1, SOD1, SOD2, STAT3, TNF, and VEGFA—a pattern consistent with neuroinflammation and neuronal apoptosis. The GO term "negative regulation of neuron apoptotic process" (GO:0043524, 11 genes) and "neuron apoptotic process" (GO:0051402, 7 genes) directly implicate neuronal cell death. Cadmium-induced neurotoxicity through disruption of essential metal homeostasis (Neuronal specific and non-specific responses to cadmium, 2019) and heavy metal interference with antioxidant defense in brain tissue (Heavy metals: toxicity and human health effects, 2024) provide mechanistic support. The substantia nigra enrichment (268.62×, BAX and TP53) specifically suggests vulnerability of dopaminergic neurons, consistent with Parkinson's disease pathway activation.

**Heart (Moderate-High Confidence)**
Cardiac tissue shows enrichment of 26+ responsive genes. The pattern of BAX, BCL2, CASP3, CAT, CDKN1A, GDF15, GPX1, HMOX1, IL1B, IL6, KEAP1, NFE2L2, NFKB1, NQO1, SIRT1, SOD1, SOD2, STAT3, TGFB1, TNF, TP53, and VEGFA in heart tissue reflects oxidative stress-mediated cardiomyopathy. GDF15 enrichment in cardiac tissue is notable as a biomarker of cardiac stress. Whey protein protection against thioacetamide-induced cardiotoxicity through modulation of these same markers (The cardioprotective effect of whey protein, 2025) validates the cardiotoxic relevance of this gene signature. Cardiomyocyte gene programs involving NFE2L2 and TP53 have been linked to cardiac hypertrophy and failure (Cardiomyocyte gene programs encoding morphological and functional signatures, 2018).

### Secondary Target Organs

**Intestine/Gastrointestinal Tract (Moderate Confidence)**
The ileum (503.67×, 6 genes including HMOX1, KEAP1, NFE2L2, NQO1, SIRT1, SOD1) and intestine (172.69×, 18+ genes) show substantial enrichment. Oyster peptide protection against intestinal oxidative damage through the KEAP1-NRF2 pathway (Protective Effect of Oyster Peptides, 2022) supports intestinal vulnerability. The inflammatory bowel disease pathway activation at high doses further implicates gastrointestinal injury.

**Testis/Reproductive Organs (Moderate Confidence)**
Testis enrichment (470.09×, 7 genes: BAX, BCL2, CASP3, CAT, GPX1, NFE2L2, TP53) and reproductive organ enrichment (503.67×) indicate gonadal toxicity potential. The RuIII/Q complex studies demonstrating amelioration of reproductive toxicity through modulation of these same genes (Potential Therapeutic Effects of New Ruthenium (III) Complex, 2021) provide direct mechanistic support.

**Lung (Moderate Confidence)**
Lung tissue (287.81×) and lung epithel

---

## Run 2 (80.3s)

# Toxicogenomic Dose-Response Interpretation Report

---

## 1. Biological Response Narrative

The 32 responsive genes (27 upregulated, 5 downregulated) across a BMD range of 0.2–20 reveal a coherent, dose-dependent progression from early adaptive cytoprotection to overt cellular damage, inflammation, and pro-apoptotic signaling.

### Ultra-Low Dose Range (BMD 0.2–0.55): Xenobiotic Sensing and Cytoprotective Activation

The earliest molecular events center on xenobiotic receptor activation and the oxidative stress defense axis. **Aryl hydrocarbon receptor (AHR) signaling** is the first pathway engaged (median BMD 0.35), with upregulation of AHR and its canonical transcriptional targets **CYP1A1** and **CYP1B1**. This represents the classical xenobiotic sensing response: ligand binding to AHR triggers nuclear translocation and induction of Phase I biotransformation enzymes. The chemical pathway for drug metabolism (path:hsa05208, median BMD 0.5) is activated concurrently, incorporating AHR, CYP1A1, and critically, the **KEAP1-NFE2L2 (NRF2)** axis along with downstream Phase II detoxification genes **HMOX1** and **NQO1**.

At BMD 0.3–0.55, the **NRF2-mediated nuclear events** and **GSK3B/BTRC:CUL1-mediated degradation of NFE2L2** pathways show mixed directionality, suggesting that while NRF2 transcriptional activity is being induced, regulatory feedback through KEAP1-dependent degradation is simultaneously engaged. The upregulation of **NFE2L2** itself, alongside **NQO1**, **HMOX1**, and **GCLC** (glutamate-cysteine ligase catalytic subunit), indicates robust activation of the antioxidant response element (ARE)-driven gene battery. This is a hallmark adaptive response to electrophilic or oxidative stress.

Metabolic pathway engagement (path:rno01100, median BMD 0.5) at this stage likely reflects the metabolic cost of Phase I/II enzyme induction and glutathione biosynthesis (GCLC upregulation).

### Low Dose Range (BMD 0.4–2.0): Ferroptosis Signaling and Early Stress Responses

Between BMD 0.4 and 2.0, **ferroptosis signaling** (path:hsa04216, median BMD 0.6) emerges, with upregulation of genes including those involved in iron-dependent lipid peroxidation defense. The engagement of **GPX1** (glutathione peroxidase 1), **SOD1**, **SOD2**, and **CAT** across this range indicates that the cell is mounting a comprehensive antioxidant defense against reactive oxygen species (ROS), including superoxide and hydrogen peroxide.

At BMD ~2.0–2.25, a notable shift occurs: **circadian clock genes** and **glucocorticoid receptor signaling** (path:hsa04922) show predominantly **downregulated** expression. Disruption of circadian transcriptional programs is increasingly recognized as an early indicator of cellular stress that precedes overt toxicity, and may reflect HIF1A-mediated metabolic reprogramming competing with circadian transcription factor binding.

### Transitional Dose Range (BMD 2.5–4.0): Emergence of Pro-Survival and Damage Signals

This range marks the critical transition from predominantly adaptive to mixed adaptive/adverse responses. **Hepatocellular carcinoma-related pathways** (path:hsa05225, median BMD 2.65) become enriched, reflecting activation of oncogenic signaling nodes including **STAT3**, **NFKB1**, **HIF1A**, and **VEGFA**. The **mitophagy** (path:hsa04137, median BMD 3.5) and **autophagy** (path:hsa04140, median BMD 3.5) pathways are upregulated, indicating that cells are engaging quality control mechanisms to remove damaged mitochondria and misfolded proteins—a response consistent with escalating oxidative damage overwhelming the primary antioxidant defenses.

The **fluid shear stress and atherosclerosis pathway** (path:hsa05418, median BMD 4.0) integrates oxidative stress (NFE2L2, HMOX1, NQO1), inflammation (IL1B, TNF, NFKB1), and cell death (TP53, BCL2) signals, suggesting that endothelial and vascular stress responses are being activated. **Wnt signaling** (path:hsa04310, median BMD 3.75) shows mixed directionality, potentially reflecting competing proliferative and growth-arrest signals.

### Moderate Dose Range (BMD 4.0–6.0): Inflammatory Cascade and Apoptotic Commitment

This dose range witnesses a dramatic expansion of adverse signaling. The **TP53 signaling pathway** (path:hsa04115, median BMD 5.5) is robustly activated, with upregulation of **TP53**, **CDKN1A** (p21), **BAX**, and **CASP3**, indicating engagement of the DNA damage response and commitment to cell cycle arrest and apoptosis. The concurrent upregulation of **TP53 Regulates Transcription of Cell Cycle Genes** (median BMD 5.25) and **TP53 Regulates Transcription of Cell Death Genes** (median BMD 5.75) confirms that p53 is functioning as a master regulator of the damage response at these doses.

The **pathways in cancer** (path:hsa05200, median BMD 5.0) become the most significantly enriched pathway (p = 5.92 × 10⁻³⁸), incorporating 15 of 26 responsive genes. This reflects not oncogenic transformation per se, but rather the activation of the same signaling hubs—**STAT3**, **NFKB1**, **HIF1A**, **VEGFA**, **TP53**, **BCL2/BAX**—that are co-opted in carcinogenesis. The **PI3K-AKT signaling pathway** (path:hsa04151, median BMD 5.25) and **HIF-1 signaling** (path:hsa04066, median BMD 5.0) indicate hypoxia-responsive and pro-survival signaling, likely reflecting tissue-level oxygen demand changes secondary to vascular and inflammatory perturbations.

**Apoptosis** (path:hsa04210, median BMD 7.0) and **cellular senescence** (path:hsa04218, median BMD 5.0) pathways are now fully engaged. The **Activation of BH3-only proteins** (median BMD 5.75) with mixed directionality (BAX up, BCL2 dynamics) indicates that the balance between pro-survival (BCL2) and pro-apoptotic (BAX) signals is shifting toward cell death.

### High Dose Range (BMD 6.0–10.0): Inflammatory Amplification and Multi-Organ Damage Signatures

At BMD 6.0–10.0, the inflammatory response reaches full amplitude. **NF-κB signaling** (path:hsa04064, median BMD 9.5), **TNF signaling** (path:hsa04668, median BMD 10.0), **IL-17 signaling** (path:hsa04657, median BMD 10.0), and **JAK-STAT signaling** (path:hsa04630, median BMD 7.0) are all upregulated, with key effectors **IL6**, **IL1B**, **TNF**, and **NLRP3** driving a robust pro-inflammatory state.

The **NLRP3 inflammasome** pathway (CLEC7A/inflammasome pathway, median BMD 12.0; Inflammasomes, median BMD 12.0) is activated at the upper end of this range, indicating pyroptotic signaling and IL-1β/IL-18 maturation. The **AGE-RAGE signaling pathway in diabetic complications** (path:hsa04933, median BMD 8.75) integrates oxidative stress, inflammation, and fibrotic signaling (TGFB1), suggesting advanced glycation end-product-like damage patterns.

**Lipid and atherosclerosis** (path:hsa05417, median BMD 8.25) now shows full engagement of 12 genes, and multiple infection/immune pathways (Hepatitis B, C; Epstein-Barr virus; HTLV-I) are enriched—not because of actual infection, but because these pathways share core inflammatory and apoptotic signaling nodes (NFKB1, STAT3, TNF, IL6, BAX, CASP3, TP53) that are activated by the toxic insult.

### Very High Dose Range (BMD 10.0–20.0): Immune Activation and Tissue Remodeling

At the highest doses, pathways related to **adaptive immune activation** emerge: **Th1/Th2 cell differentiation** (path:hsa04658), **T cell receptor signaling** (path:hsa04660, median BMD 9.5), **natural killer cell-mediated cytotoxicity** (path:hsa04650, median BMD 9.0), and **hematopoietic cell lineage** (path:hsa04640, median BMD 11.0). This suggests recruitment and activation of immune cells in response to tissue damage (damage-associated molecular patterns, DAMPs).

**TGF-beta signaling** (path:hsa04350, median BMD 12.5) and the **Senescence-Associated Secretory Phenotype (SASP)** (median BMD 10.25) indicate that surviving cells are entering a senescent state characterized by secretion of pro-inflammatory and pro-fibrotic mediators, consistent with tissue remodeling and potential fibrogenesis. The **dilated cardiomyopathy** (path:hsa05414, median BMD 12.5) and **hypertrophic cardiomyopathy** (path:hsa05410, median BMD 12.0) pathway enrichment at these doses suggests cardiac tissue remodeling as a late consequence.

---

## 2. Organ-Level Prediction

### Primary Target Organs

#### Liver (Highest Confidence)
The liver emerges as the most probable primary target organ based on multiple converging lines of evidence:

- **Gene signature**: 31+ genes from the responsive set show liver-associated expression (enrichment 45.06×), including the complete AHR-CYP1A1/CYP1B1 xenobiotic metabolism axis, the KEAP1-NFE2L2-NQO1-HMOX1-GCLC antioxidant battery, inflammatory mediators (IL6, IL1B, TNF, NFKB1), apoptotic regulators (BAX, BCL2, CASP3, TP53), and metabolic sensors (PPARA, SIRT1).
- **Pathway concordance**: The early activation of AHR signaling and Phase I/II metabolism is characteristic of hepatic first-pass metabolism. The progression to NF-κB-mediated inflammation, TP53-dependent apoptosis, and TGFB1-driven fibrotic signaling recapitulates the well-established adverse outcome pathway for drug-induced liver injury (DILI).
- **Literature support**: Quantitative transcriptional biomarkers for xenobiotic receptor activation in rat liver, including AHR and NFE2L2 targets, have been validated as predictors of DILI (Quantitative Transcriptional Biomarkers of Xenobiotic Receptor Activation, 2020). Cadmium-induced toxicity in hepatic macrophages (Kupffer cells) activates NF-κB and NRF2, alters macrophage polarization, and promotes hepatic inflammation and fibrosis (Research Advances on Cadmium-Induced Toxicity in Hepatic Macrophages, 2026). The enrichment of **Hepatic Kupffer Cells** (671.56× for HMOX1) further supports hepatic involvement.
- **Mechanistic coherence**: The dose-ordered activation of AHR → NRF2 → TP53 → NF-κB/inflammation → TGFB1/fibrosis mirrors the canonical hepatotoxicity progression from metabolic activation through oxidative stress to inflammation and fibrosis.

#### Kidney (High Confidence)
The kidney is the second most likely target organ:

- **Gene signature**: 26+ genes show kidney-associated expression (enrichment 75.59×), including the complete oxidative stress defense panel (NFE2L2, HMOX1, NQO1, GCLC, GPX1, SOD1, SOD2, CAT), apoptotic markers (BAX, BCL2, CASP3, TP53), and inflammatory mediators.
- **Organ-specific markers**: **Renal Tubular Epithelium** shows 671.56× enrichment for HMOX1, and **HAVCR1** (KIM-1, a validated renal injury biomarker) is among the responsive genes in the xenobiotic stimulus GO term.
- **Literature support**: Nanocurcumin mitigates doxorubicin-induced nephrotoxicity by modulating VEGF and AhR pathways (Aryl Hydrocarbon Receptor and Vascular Endothelial Growth Factor, 2026). Fenofibrate differentially activates PPARα-mediated lipid metabolism in kidney with organ-specific toxicity (Fenofibrate differentially activates PPARα, 2025).
- **Pathway concordance**: AGE-RAGE signaling in diabetic complications (path:hsa04933) is strongly associated with diabetic nephropathy, and its enrichment (10 genes, median BMD 8.75) suggests renal tubular damage at moderate-to-high doses.

#### Heart (Moderate-High Confidence)
Cardiac tissue shows substantial gene signature overlap:

- **Gene signature**: 26+ genes with cardiac expression (enrichment 51.35×), including the complete stress response panel plus cardiac-specific pathway enrichment for dilated cardiomyopathy (path:hsa05414, median BMD 12.5) and hypertrophic cardiomyopathy (path:hsa05410, median BMD 12.0).
- **Organ-specific markers**: **Pericardium** (335.78× enrichment for IL1B, IL6), **Right Ventricle** (83.95× for IL1B, TNF), **Left Ventricular Myocardium** (111.93× for VEGFA), and **Cardiac Microvasculature** (223.85× for TGFB1) all show significant enrichment.
- **Literature support**: Whey protein pre-treatment alleviates thioacetamide-induced cardiotoxicity by reducing oxidative stress, inflammatory response, and apoptotic markers including CASP3, BAX, BCL2, TNF, and IL1B (The cardioprotective effect of whey protein, 2025). Cardiomyocyte gene programs in cardiac hypertrophy and failure involve NFE2L2 and TP53 (Cardiomyocyte gene programs, 2018).
- **Mechanistic basis**: The late activation of cardiomyopathy pathways (BMD 12.0–12.5) suggests cardiac effects are secondary to systemic inflammation and oxidative stress rather than direct cardiotoxicity.

#### Brain/Central Nervous System (Moderate Confidence)
Neurotoxicity is supported by:

- **Gene signature**: 21+ genes with brain expression (enrichment 67.48×), including neuronal survival genes (BAX, BCL2, SIRT1, SOD1, SOD2), inflammatory mediators (IL1B, IL6, TNF), and the NRF2 axis.
- **Organ-specific markers**: **Cingulate Cortex** (671.56× for NFE2L2), **Neurons** (184.68× for 13+ genes), **Substantia Nigra** (268.62× for BAX, TP53), **Hippocampal CA1 Region** (191.88× for BAX, BCL2), and **Neurodegenerative Tissues** (503.67× for BAX, BCL2, NFE2L2).
- **Literature support**: Cadmium-induced neurotoxicity in SH-SY5Y cells involves p53 signaling, heat shock proteins, and disruption of essential metal homeostasis (Neuronal specific and non-specific responses to cadmium, 2019). Selective cytotoxicity of amyloid β through p53 and BAX

---

## Run 3 (77.1s)

# Toxicogenomic Dose-Response Interpretation Report

---

## 1. Biological Response Narrative

The 32 responsive genes (27 upregulated, 5 downregulated) across a BMD range of 0.2–20 reveal a coherent, dose-dependent progression from early adaptive cytoprotection to overt cellular damage, inflammation, and programmed cell death.

### Ultra-Low Dose Range (BMD 0.2–0.5): Xenobiotic Sensing and Phase I/II Metabolism

The earliest molecular events center on aryl hydrocarbon receptor (AHR) signaling, with AHR pathway activation detected at a median BMD of 0.35 (3 genes, predominantly upregulated). This is immediately followed by engagement of the chemical carcinogenesis–reactive oxygen species pathway (path:hsa05208/rno05208; median BMD 0.5; 9 genes including AHR, CYP1A1, HIF1A, HMOX1, KEAP1, NFE2L2, NFKB1, NQO1, VEGFA). Concurrently, metabolic pathway genes (path:rno01100/hsa01100; median BMD 0.5) are activated, reflecting engagement of Phase I biotransformation enzymes (CYP1A1, CYP1B1) and early Nrf2-dependent Phase II detoxification.

At this dose tier, the response is dominated by xenobiotic recognition and metabolic activation. AHR-mediated transcriptional induction of CYP1A1 and CYP1B1 represents the canonical xenobiotic-sensing response, consistent with the compound acting as an AHR ligand or generating AHR-activating metabolites. The simultaneous appearance of NFE2L2 (Nrf2) nuclear events and KEAP1-mediated regulatory processes (median BMD 0.55) indicates that oxidative or electrophilic stress is generated as a direct consequence of Phase I metabolism, triggering the Keap1-Nrf2-ARE cytoprotective axis.

### Low Dose Range (BMD 0.5–2.0): Oxidative Stress Defense and Early Ferroptosis Signaling

Between BMD 0.5 and 2.0, the response broadens to include biosynthesis of cofactors (path:rno01240/hsa01240; median BMD 0.55), ferroptosis-related pathways (path:hsa04216/rno04216; median BMD 0.6; genes including GPX1, GCLC), and cushing syndrome-related signaling (path:hsa04934/rno04934; median BMD 2.35). The upregulation of GCLC (glutamate-cysteine ligase catalytic subunit), GPX1 (glutathione peroxidase 1), NQO1 (NAD(P)H quinone dehydrogenase 1), CAT (catalase), SOD1, and SOD2 at these doses reflects a robust antioxidant defense mobilization. These enzymes collectively neutralize reactive oxygen species (ROS), maintain glutathione homeostasis, and protect against lipid peroxidation.

Notably, the ferroptosis pathway activation at BMD 0.6 is significant: the upregulation of GPX1 and GCLC at this stage likely represents a protective response against iron-dependent lipid peroxidation rather than active ferroptotic cell death. The downregulation observed in the circadian clock pathway (median BMD 2.25; 2 genes, mostly DOWN) suggests early disruption of circadian transcriptional regulation, which may reflect metabolic stress or direct interference with clock gene networks.

### Moderate Dose Range (BMD 2.0–5.0): Transition to Damage Signaling

This dose range marks a critical inflection point where protective responses begin to be overwhelmed and damage-associated pathways emerge.

**Hepatocellular carcinoma-related signaling** (path:hsa05225/rno05225; median BMD 2.65; 8 genes) and **mitophagy** (path:rno04137/hsa04137; median BMD 3.5; 3 genes) are activated, indicating mitochondrial stress and quality control responses. The concurrent activation of **autophagy** (path:rno04140/hsa04140; median BMD 3.5; 3 genes including SQSTM1) and **Wnt signaling** (path:hsa04310/rno04310; median BMD 3.75) suggests cellular attempts to manage damaged organelles and maintain tissue homeostasis.

By BMD 4.0, the fluid shear stress and atherosclerosis pathway (path:rno05418/hsa05418; 11 genes) and chemical carcinogenesis–receptor activation pathway (path:rno05207/hsa05207; 7 genes) are fully engaged. The former pathway includes BCL2, HMOX1, IL1B, KEAP1, NFE2L2, NFKB1, NQO1, SQSTM1, TNF, TP53, and VEGFA—a signature reflecting the convergence of oxidative stress, inflammatory, and vascular injury responses.

The **TP53 signaling pathway** (path:rno04115/hsa04115; median BMD 5.5; 5 genes) and **cell cycle** (path:rno04110/hsa04110; median BMD 5.0; 3 genes) become active, with upregulation of TP53, CDKN1A (p21), and BAX indicating DNA damage checkpoint activation and cell cycle arrest. The concurrent upregulation of CDKN1A (a direct p53 transcriptional target) confirms functional p53 pathway engagement.

### Moderate-High Dose Range (BMD 5.0–8.0): Inflammation, Apoptosis, and Tissue Injury

The pathways in cancer (path:rno05200/hsa05200; median BMD 5.0; 15 genes) now reach full activation, encompassing the complete spectrum of oncogenic stress responses: apoptosis regulators (BAX, BCL2, CASP3), cell cycle control (CDKN1A, TP53), angiogenesis (VEGFA, HIF1A), inflammation (IL6, NFKB1), and cytoprotection (NFE2L2, NQO1, HMOX1).

**Apoptotic signaling** intensifies with activation of BH3-only proteins (median BMD 5.75), TP53-regulated cell death genes (median BMD 5.75), and the apoptosis pathway proper (path:hsa04210/rno04210; median BMD 7.0; 6 genes). The upregulation of BAX (pro-apoptotic) alongside BCL2 (anti-apoptotic) suggests a dynamic balance, but the predominant upward direction of BAX and CASP3 (caspase-3, the executioner caspase) indicates net pro-apoptotic signaling.

**Inflammatory cascades** escalate with activation of the AGE-RAGE signaling pathway in diabetic complications (path:hsa04933/rno04933; median BMD 8.75; 10 genes including IL1B, IL6, TNF, NFKB1, STAT3, TGFB1), NF-κB signaling (path:hsa04064/rno04064; median BMD 9.5), and JAK-STAT signaling (path:hsa04630/rno04630; median BMD 7.0). The upregulation of the master inflammatory cytokines TNF, IL1B, and IL6, together with their transcriptional regulators NFKB1 and STAT3, indicates a full inflammatory response.

**Lipid and energy metabolism** pathways including PPAR signaling, insulin resistance (path:hsa04931/rno04931; median BMD 9.0), and adipocytokine signaling (path:hsa04920/rno04920; median BMD 8.75) are perturbed, consistent with metabolic disruption secondary to oxidative stress and inflammation.

### High Dose Range (BMD 8.0–20): Immune Activation, Fibrosis, and Systemic Toxicity

At the highest doses, the response profile shifts toward innate and adaptive immune activation, with engagement of Toll-like receptor signaling (path:hsa04620/rno04620; median BMD 10.5), NOD-like receptor signaling (path:hsa04621/rno04621; median BMD 10.5), RIG-I-like receptor signaling (path:hsa04622/rno04622; median BMD 9.5), and cytokine-cytokine receptor interaction (path:hsa04060/rno04060; median BMD 11.0). The NLRP3 inflammasome pathway (median BMD 12.0) and the senescence-associated secretory phenotype (SASP; median BMD 10.25) are activated, indicating sterile inflammation and cellular senescence.

The upregulation of TGFB1 at higher doses, combined with VEGFA and HIF1A, suggests progression toward fibrogenic and angiogenic remodeling responses. Multiple infection-related pathways (Shigellosis, Salmonella, Legionellosis, Tuberculosis, etc.) are enriched at BMD 10–13, reflecting the engagement of generic innate immune defense modules rather than actual infection—these pathways share core inflammatory and apoptotic effectors (TNF, IL1B, IL6, NFKB1, CASP3, BAX) that are activated by sterile tissue injury.

---

## 2. Organ-Level Prediction

### Primary Target Organs

**Liver (enrichment score 45.06x; 31+ genes)**

The liver emerges as the most comprehensively affected organ based on the breadth of gene involvement (AHR, BAX, BCL2, CASP3, CAT, CDKN1A, CYP1A1, CYP1B1, GCLC, GPX1, HMOX1, IL6, KEAP1, NFE2L2, NFKB1, NQO1, PPARA, SIRT1, SOD1, SOD2, SQSTM1, STAT3, TGFB1, TNF, TP53, VEGFA, and others). The early activation of AHR-CYP1A1/CYP1B1 xenobiotic metabolism, followed by Nrf2-mediated detoxification, and subsequent NF-κB-driven inflammation recapitulates the canonical hepatotoxicity progression. The literature strongly supports this interpretation: quantitative transcriptional biomarkers for xenobiotic receptor activation (AHR, PPARA, NFE2L2) in rat liver predict drug-induced liver injury (DILI) with high sensitivity and specificity (Quantitative Transcriptional Biomarkers of Xenobiotic Receptor Activation, 2020). The activation of hepatic Kupffer cell markers (HMOX1, enrichment 671.56x) and the cadmium-induced toxicity literature describing NF-κB and Nrf2 activation in hepatic macrophages (Research Advances on Cadmium-Induced Toxicity in Hepatic Macrophages, 2026) further support hepatotoxicity as a primary outcome.

**Kidney (enrichment score 75.59x; 26+ genes)**

The kidney shows the second-highest gene coverage with involvement of AHR, BAX, BCL2, CASP3, CDKN1A, CYP1A1, CYP1B1, GCLC, GPX1, HMOX1, IL6, KEAP1, NFE2L2, NFKB1, NQO1, PPARA, SIRT1, SOD1, SOD2, SQSTM1, STAT3, TGFB1, TNF, TP53, and VEGFA. The renal tubular epithelium signature (HMOX1, enrichment 671.56x) is particularly notable, as HMOX1 induction is a well-established biomarker of renal oxidative injury. The literature on nanocurcumin mitigating doxorubicin-induced nephrotoxicity via VEGF and AhR pathways (Aryl Hydrocarbon Receptor and Vascular Endothelial Growth Factor, 2026) and fenofibrate-induced organ-specific PPARα-mediated toxicity in kidney (Fenofibrate differentially activates PPARα-mediated lipid metabolism, 2025) support renal vulnerability.

**Heart (enrichment score 51.35x; 26+ genes)**

Cardiac tissue shows extensive gene involvement including AHR, BAX, BCL2, CASP3, CAT, CDKN1A, GDF15, GPX1, HMOX1, IL1B, IL6, KEAP1, NFE2L2, NFKB1, NQO1, SIRT1, SOD1, SOD2, STAT3, TGFB1, TNF, TP53, and VEGFA. The pericardium (IL1B, IL6; 335.78x), right ventricle (IL1B, TNF; 83.95x), and left ventricular myocardium (VEGFA; 111.93x) signatures suggest both inflammatory and vascular injury. The cardiomyocyte gene program literature (Cardiomyocyte gene programs encoding morphological and functional signatures, 2018) and whey protein cardioprotection studies (The cardioprotective effect of whey protein, 2025) confirm the relevance of these gene signatures to cardiac pathology.

### Secondary Target Organs

**Brain/Central Nervous System (enrichment score 67.48x; 21+ genes)**

The CNS shows strong enrichment across multiple sub-regions: cingulate cortex (NFE2L2; 671.56x), substantia nigra (BAX, TP53; 268.62x), hippocampal CA1 region (BAX, BCL2; 191.88x), neurons (11+ genes; 184.68x), and brain tissue (BAX, BCL2, CASP3, VEGFA; 447.71x). The neurodegenerative disease pathway enrichment (Alzheimer's, Parkinson's; path:hsa05012, path:hsa05014, path:hsa05020, path:hsa05010) and the GO term "negative regulation of neuron apoptotic process" (11 genes, FDR 2.80×10⁻¹³) indicate neurotoxic potential. Literature on cadmium-induced neurotoxicity in SH-SY5Y cells (Neuronal specific and non-specific responses to cadmium, 2019) and Zn/Se protection against heavy metal-mediated memory deficits (Zn and Se protect toxic metal mixture-mediated memory deficits, 2025) support this prediction.

**Intestine (enrichment score 172.69x; 18+ genes)**

The gastrointestinal tract, particularly the ileum (503.67x; HMOX1, KEAP1, NFE2L2, NQO1, SIRT1, SOD1), shows high enrichment. The intestinal Nrf2-Keap1 axis activation is consistent with the oyster peptide intestinal protection literature (Protective Effect of Oyster Peptides, 2022), suggesting the gut epithelium is a direct target of oxidative injury.

**Testis/Reproductive Organs (enrichment score 470.09x; 7 genes)**

The testis (BAX, BCL2, CASP3, CAT, GPX1, NFE2L2, TP53) and reproductive organs (BAX, BCL2, NFE2L2; 503.67x) show high enrichment, consistent with reproductive toxicity. The RuIII/Q complex literature describing amelioration of aging-induced reproductive toxicity (Potential Therapeutic Effects of New Ruthenium (III) Complex, 2021) confirms the relevance of these apoptotic and oxidative stress markers in testicular tissue.

**Lung (enrichment score 44.62x; 20+ genes)**

Pulmonary tissue shows involvement of multiple gene classes including xenobiotic metabolism (CYP1A1), antioxidant defense (CAT, GCLC, GPX1, SOD2), inflammation (IL6, TNF, NFKB1), and apoptosis (BAX, BCL2, CASP3). The lung epithelium (CYP1A1; 335.78x) and lung fibroblasts (CYP1B1; 671.56x) signatures suggest both epithelial and mesenchy

---
